|
Infliximab Concentration & Ab
INFLIXIMAB
Synonyms
|
|
Allscripts (AEHR) Order Name
|
Infliximab Concentration & Ab
|
Sunrise Clinical Manager (SCM) Order Name
|
Infliximab Concentration and Antibody
|
EPIC Order Name
|
Infliximab Concentration and Infliximab Antibody
|
Clinical Info
|
Provides infliximab drug concentration levels as well as levels of anti-infliximab antibodies.
In the absence of anti-infliximab antibodies, the infliximab drug level typically reflects the total infliximab concentration in serum. In the presence of anti-infliximab antibodies, the infliximab drug level typically reflects the antibody-unbound fraction of infliximab concentration in serum. The presence of infliximab drug, even at concentrations well above target treatment levels (>50 μg/mL), does not interfere with the anti-infliximab antibody detection. This assay may be helpful for any patients on infliximab therapy for diseases such as Crohn's disease, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or other autoimmune conditions.
Limitations
Failure of infliximab therapy may not always be due to the presence of anti-infliximab antibodies. In addition, the absence of anti-infliximab antibodies does not guarantee positive response to treatment.
High serum biotin concentrations in patients taking biotin supplements may cause an interference in this assay. Patients may be advised to stop biotin consumption at least 72 hours prior to sample collection.
|
Specimen Type
|
Blood
|
Container
|
Gold Top Tube
|
Collection Instructions
|
Container/Tube: Gold top or Red top tube
Specimen: 2 ml serum (1 mL min- does not allow for repeat testing)
Transport Temperature: Refrigerated
Stability: 7 Days Room Temperature
7 Days Refrigerated
359 Days Frozen
Note: Serum must be separated from cells within 45 minutes of venipuncture
|
Transport Instructions
|
Refrigerated
|
Specimen Stability
|
7 Days Room Temperature
7 Days Refrigerated
359 Days Frozen
Note: Serum must be separated from cells within 45 minutes of venipuncture
|
Methodology
|
Electrochemiluminescence immunoassay (ECLIA)
|
Days Performed
|
|
Performing Laboratory
|
LabCorp of America
|
CPT
|
80299
82397
|
PDM
|
5963016
|
Result Interpretation
|
Infliximab drug level:
|
<0.4 µg/mL
|
|
• Result ≥0.4 µg/mL
indicates detection of infliximab.
|
• In the presence of anti-infliximab antibodies, the
infliximab drug level reflects the antibody-unbound fraction of
infliximab concentration in serum.
|
Anti-infliximab antibody:
|
<22 ng/mL
|
|
• Result ≥22 ng/mL indicates
detection of anti-infliximab antibodies.
|
|
Forms
|
|
|